We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Triple Drug Cocktail Antiviral Therapy Alleviates COVID-19 Symptoms and Shortens Hospital Stay, Finds New Study

By HospiMedica International staff writers
Posted on 12 May 2020
A new study has found that patients with mild to moderate COVID-19 who received a triple-drug treatment improved more quickly than those who received a two-drug combination.

The cocktail included three antiviral drugs: lopinavir-ritonavir (sold under the brand name Kaletra), taken orally; ribavirin, an antiviral drug for the treatment of hepatitis C, taken orally; and interferon beta-1b, an injectable drug that is used to treat multiple sclerosis and regulates inflammation and suppresses viral growth. More...
The participants in the comparison group who were treated with a two-drug combination received only lopinavir and ritonavir.

According to the new study published in The Lancet, researchers in Hong Kong followed 127 adults with COVID-19, including 86 patients who received the three-drug cocktail and 41 in the comparison group. The researchers found that patients who were given the cocktail of three antiviral drugs tested negative for the coronavirus within an average of seven days, as compared to an average of 12 days for those treated with the two-drug combination of lopinavir and ritonavir. The study also found that the triple-drug combination appeared to make the patients recover faster and cut the duration of their COVID-19 symptoms from eight days to four days.

Additionally, the triple-drug treatment appeared to be safe and both the groups experienced similar side effects, such as fever, nausea and diarrhea. The researchers now plan to conduct a larger trial to examine the effectiveness of the triple-drug treatment in critically ill COVID-19 patients.



Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Medical Adhesive
MED 5570U
Hypodermic Syringe
SurTract™ Safety Syringe
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
image: Principles of SMEAR-ULM. (Lai, Y., Argüello, A.N., Liu, M. et al., Nature Sensors (2026). DOI: 10.1038/s44460-026-00078-4)

“Intelligent Tattoo” Method Detects Early Melanoma Signals

Melanoma is a lethal skin cancer in which earlier detection drives better outcomes. Current evaluation relies on visual inspection followed by biopsy, which can miss nascent lesions and lead to unnecessary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.